Yehud-based biotechnology start-up BioControl Medical said Wednesday it was enrolling patients for an international, multi-center, open-label study of its CardioFit system for the treatment of congestive heart failure system at sites in Europe, Israel and Australia.
CardioFit is an electrical stimulator system designed to improve heart function through the controlled stimulation of the vagus nerve. Early data show that the CardioFit system is safe to implant in patients with NYHA class III heart failure, the company said.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>